Terms: = Lymphoma AND MSI2, ENSG00000153944, 124540 AND Treatment
3 results:
1. Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone.
Zou D; Lv M; Chen Y; Niu T; Ma C; Shi C; Huang Z; Wu Y; Yang S; Wang Y; Wu N; Zhang Y; Ouyang G; Mu Q
Ann Hematol; 2024 Jan; 103(1):141-151. PubMed ID: 37749318
[TBL] [Abstract] [Full Text] [Related]
2. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T; Evans CM; Zakheim D; Chu KL; Refermat AY; Asgari Z; Yang X; Da Silva Ferreira M; Mehta S; Russo MV; Knezevic A; Zhang XP; Chen Z; Fennell M; Garippa R; Seshan V; de Stanchina E; Barbash O; Batlevi CL; Leslie CS; Melnick AM; Younes A; Kharas MG
Nat Commun; 2022 Sep; 13(1):5676. PubMed ID: 36167829
[TBL] [Abstract] [Full Text] [Related]
3. High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia.
Mu Q; Wang Y; Chen B; Qian W; Meng H; Tong H; Chen F; Ma Q; Ni W; Chen S; Jin J
Leuk Res; 2013 Aug; 37(8):922-7. PubMed ID: 23759245
[TBL] [Abstract] [Full Text] [Related]
